Risk factors associated with calcinosis of juvenile dermatomyositis

Sallum, Adriana Maluf Elias; Pivato, Francine C. M. M.; Doria-Filho, Ulysses; Aikawa, Nádia E.; Liphaus, Bernadete L.; Marie, Suely Kazue Nagahashi; Silva, Clóvis A.

doi:10.2223/jped.1746

Cited by 31 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that patients with higher muscle-derived enzyme levels had a lower incidence of calcinosis, probably because of the more aggressive treatment regimen. 19 In contrast, Sallum et al 15 observed that patients with severe cases of JDM (eg, with cardiac involvement) receiving immunosuppressant therapy had a higher risk of developing calcinosis.…”

Section: Learning Objectivesmentioning

confidence: 96%

“…13,14 Skin calcification is frequently observed in dermatomyositis (Figs 4 and 5). According to Sallum et al, 15 calcinosis cutis can be found in 30% of adults and in up to 70% of children and adolescents with dermatomyositis. The disease itself is an inflammatory myopathy that is characterized by skin involvement and muscular weakness.…”

Section: Learning Objectivesmentioning

confidence: 99%

See 1 more Smart Citation

Calcinosis cutis

Reiter¹,

El-Shabrawi²,

Leinweber³

et al. 2011

Journal of the American Academy of Dermatology

234

149

View full text Add to dashboard Cite

Section: Learning Objectivesmentioning

confidence: 96%

Section: Learning Objectivesmentioning

confidence: 99%

Calcinosis cutis

Reiter¹,

El-Shabrawi²,

Leinweber³

et al. 2011

Journal of the American Academy of Dermatology

234

149

View full text Add to dashboard Cite

“…The delay in starting treatment and the severity of the disease are risk factors for the development of calcinosis. 20 Other relatively frequent lesions were cutaneous ulcers and vasculitides, which, in addition to being possible signs of the severity of the disease, are secondary infection areas. In fact, in the present study, a high prevalence of cellulitis and abscesses was observed, also contributing to increase morbidity and mortality.…”

Section: Discussionmentioning

confidence: 99%

Dermatomiosite em adulto: experiência de um centro terciário brasileiro

Souza¹,

Barros²,

Levy‐Neto³

et al. 2012

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Objective: To report the results of a retrospective cohort involving 139 patients with dermatomyositis, conducted from 1991 to 2011. Methods: All patients met at least four of the fi ve Bohan and Peter criteria (1975). Results: The patients' mean age at disease onset was 41.7 ± 14.1 years, and mean disease duration was 7.2 ± 5.2 years. The sample comprised 90.2% white patients and 79.9% female patients. Constitutional symptoms occurred in less than half of the patients. Cutaneous and joint involvements occurred in 95.7% and 41.7% of the patients, respectively. Incipient pneumopathy, ground glass opacities and/or pulmonary fi brosis were present in 48.2% of the patients. All patients received prednisone (1 mg/kg/day) and 51.1% also received intravenous methylprednisolone (1 g/day for three days). Several immunosuppressants were used as corticosteroid sparing agents according to tolerance, side effects and/or refractoriness. Although disease relapse (clinical and/or laboratory) occurred in 53.2% of the patients, 76.3% were in disease remission at the end of the study. The rate of severe infection was 35.3%, and herpes zoster predominated. There were 15 (10.8%) cases of cancer, 12 within one year after the diagnosis. There were 16 deaths (11.5%), and their major causes were sepsis/septic shock (27.5%), pneumopathy attributed to the disease (31.3%), neoplasms (31.3%), and cardiovascular events (12.5%). Conclusions: In this study, the clinical and laboratory data were similar to those of other population groups described in the literature, with minimal differences regarding the frequency and characteristics of the extramuscular manifestations.

show abstract

“…Unlike adults with dermatomyositis, calcinosis is more common in JDM as it occurs in up to 70% of cases [1]. Although it may precede JDM diagnosis [2], its development was related to delayed diagnosis and treatment and chronicity of JDM [3].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Rituximab Therapy on Severe Calcinosis in 4 Children with Juvenile Dermatomyositis

Alhemairi¹,

Muzaffer²

2017

OJRA

View full text Add to dashboard Cite

Background: Calcinosis is an important sequela of JDM which may cause significant morbidity and mortality. There is no standard curative treatment for calcinosis but different agents were used with variable efficacy. We report the favorable outcome of rituximab on severe calcinosis in 4 JDM patients and present their clinical data. Patients and Methods: A retrospective chart review of 4 children with JDM and severe calcinosis who received rituximab for relapsing or polycyclic JDM course. Diagnosis and follow up of calcinosis was clinically and by X-ray. Review data included: age of patients at onset of JDM symptoms and diagnosis, clinical and laboratory criteria at diagnosis, disease course and duration of follow up. Data about calcinosis onset, sites, severity and its progression were also included. Further data about rituximab therapy included: dosage, side effects, other treatment used before, during or after this drug and outcome and duration of follow up of calcinosis after therapy. Results: 4 patients (2 male, 2 female), interval between onset of symptoms and diagnosis was 6 -12 months, course of JDM was polycyclic or relapsing, duration of follow up was 5 -7 years. Calcinosis was severe causing ulceration, recurrent skin infections and joint limitation. It was not improving despite treatment with different DMARDs and/or bisphosphonates, colchicine and warfarin. Reason to start rituximab was inadequate disease control with conventional DMARDs. All patients received steroids and more than one DMARD before starting rituximab and were continued thereafter, follow up after rituximab was 3 to 5 years. All patients had improvement in disease activity and frequency of admission especially due to complications of calcinosis. One patient had complete clearance of calcinosis for the last 5 years. Others had significant improvement in calcinosis with no new lesions, decreased sites and density and decreased calcinosis related contractures. There were no serious side effects to rituximab. Conclusion: Our study showed the favorable effect of rituximab in treatment of calcinosis in 4 patients with JDM-associated severe calcinosis when it was used with other conventional DMARDs.

show abstract

Risk factors associated with calcinosis of juvenile dermatomyositis

Cited by 31 publications

References 24 publications

Calcinosis cutis

Calcinosis cutis

Dermatomiosite em adulto: experiência de um centro terciário brasileiro

Effectiveness of Rituximab Therapy on Severe Calcinosis in 4 Children with Juvenile Dermatomyositis

Contact Info

Product

Resources

About